Validation of the oral mucositis assessment scale in pediatric cancer

Authors

  • Lillian Sung MD, PhD,

    Corresponding author
    1. Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
    2. Department of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    3. Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
    • Division of Hematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.
    Search for more papers by this author
  • George A. Tomlinson PhD,

    1. Department of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    2. Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    3. Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
    Search for more papers by this author
  • Mark L. Greenberg MBBS,

    1. Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
    2. Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Search for more papers by this author
  • Gideon Koren MD,

    1. Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
    2. Department of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    3. Division of Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Search for more papers by this author
  • Peter Judd DDS, MSc,

    1. Department of Dentistry, The Hospital for Sick Children, Toronto, Ontario, Canada
    Search for more papers by this author
  • Sylvia Ota BSc,

    1. Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
    Search for more papers by this author
  • Brian M. Feldman MD, MSc

    1. Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
    2. Department of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    3. Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
    4. Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Search for more papers by this author

Abstract

Background

Our objective was to examine the construct validity of the Oral Mucositis Assessment Scale (OMAS) in children receiving doxorubicin chemotherapy.

Methods

Children between 6 and 18 years of age with cancer receiving doxorubicin-containing chemotherapy were included. OMAS was measured on days 7, 10, 14, and 17 after chemotherapy. Other measures of mucositis obtained concurrent with OMAS were the World Health Organization (WHO) mucositis scale and pain visual analogue scale (VAS). We also recorded analgesia administration.

Results

Sixteen children were studied for 45 post-chemotherapy cycles and 156 OMAS assessments were performed. OMAS was moderately correlated with WHO scores (r = 0.56; P = 0.0006) whereas correlation with the pain VAS was fair (r = 0.37; P = 0.002). OMAS also had fair correlation with the number of doses of topical analgesia (r = 0.43; P = 0.001) and with the cumulative dose of opioid analgesia (r = 0.38; P = 0.003).

Conclusions

The OMAS is valid for use in mucositis clinical trials for children at least 6 years of age. Pediatr Blood Cancer 2007;49:149–153. © 2006 Wiley-Liss, Inc.

Ancillary